Abstract
This study demonstrates the unique clinical and histologic aspects of fibrolamellar hepatic carcinoma, a rare variant of hepatocellular carcinoma. Three cases are reviewed and an extensive study of immunologic and intracellular substances defining this tumor is presented. Length of survival was considerably longer than typical hepatoma. The cause of death generally is due to a lack of control of the primary tumor. Successful treatment appears to relate to the ability to perform a total excision of the primary hepatic tumor. Chemotherapy should be used only in the presence of metastatic disease. Surgical resection of metastatic disease, unlike the usual hepatocarcinoma, may have some beneficial use. Fibrinogen was found in all tumors. It is possible that this tumor produces fibrinogen to create its unique histologic appearance. Carcinoembryonic antigen is described for the first time in this tumor. Both deposits of alpha-1 antitrypsin and copper were found in most of the tissues studied. The presence and amounts of these substances differ markedly from the common type of hepatoma. This unique composition of intracellular components may both facilitate histologic diagnosis, particularly if the amount of tissue is limited, and give further insight into the etiology of this tumor.
Full text
PDFImages in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berman M. M., Libbey N. P., Foster J. H. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma--an atypical variant with a favorable prognosis. Cancer. 1980 Sep 15;46(6):1448–1455. doi: 10.1002/1097-0142(19800915)46:6<1448::aid-cncr2820460626>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
- Collier N. A., Weinbren K., Bloom S. R., Lee Y. C., Hodgson H. J., Blumgart L. H. Neurotensin secretion by fibrolamellar carcinoma of the liver. Lancet. 1984 Mar 10;1(8376):538–540. doi: 10.1016/s0140-6736(84)90934-6. [DOI] [PubMed] [Google Scholar]
- Craig J. R., Peters R. L., Edmondson H. A., Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980 Jul 15;46(2):372–379. doi: 10.1002/1097-0142(19800715)46:2<372::aid-cncr2820460227>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
- Falkson G., Moertel C. G., Lavin P., Pretorius F. J., Carbone P. P. Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer. 1978 Nov;42(5):2149–2156. doi: 10.1002/1097-0142(197811)42:5<2149::aid-cncr2820420510>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
- Farhi D. C., Shikes R. H., Silverberg S. G. Ultrastructure of fibrolamellar oncocytic hepatoma. Cancer. 1982 Aug 15;50(4):702–709. doi: 10.1002/1097-0142(19820815)50:4<702::aid-cncr2820500414>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- Govindarajan S., Ashcavai M., Peters R. L. alpha-1-Antitrypsin phenotypes in hepatocellular carcinoma. Hepatology. 1981 Nov-Dec;1(6):628–631. doi: 10.1002/hep.1840010611. [DOI] [PubMed] [Google Scholar]
- Lefkowitch J. H., Muschel R., Price J. B., Marboe C., Braunhut S. Copper and copper-binding protein in fibrolamellar liver cell carcinoma. Cancer. 1983 Jan 1;51(1):97–100. doi: 10.1002/1097-0142(19830101)51:1<97::aid-cncr2820510120>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
- Macnab G. M., Urbanowicz J. M., Kew M. C. Carcinoembryonic antigen in hepatocellular cancer. Br J Cancer. 1978 Jul;38(1):51–54. doi: 10.1038/bjc.1978.162. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mathew T., Gupta R. K. Isoantigens A, B and H in primary liver malignancies. Pathology. 1981 Jul;13(3):571–577. doi: 10.3109/00313028109059074. [DOI] [PubMed] [Google Scholar]
- McCormack P. M., Bains M. S., Beattie E. J., Jr, Martini N. Pulmonary resection in metastatic carcinoma. Chest. 1978 Feb;73(2):163–166. doi: 10.1378/chest.73.2.163. [DOI] [PubMed] [Google Scholar]
- Nazarewicz-de Mezer T., Slusarczyk J., Krawczynski K., Nowoslawski A. Localization of hepatitis B virus antigens in hepatocellular carcinoma. Prog Med Virol. 1981;27:66–76. [PubMed] [Google Scholar]
- Paradinas F. J., Melia W. M., Wilkinson M. L., Portmann B., Johnson P. J., Murray-Lyon I. M., Williams R. High serum vitamin B12 binding capacity as a marker of the fibrolamellar variant of hepatocellular carcinoma. Br Med J (Clin Res Ed) 1982 Sep 25;285(6345):840–842. doi: 10.1136/bmj.285.6345.840. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rosenburg S. A., Flye M. W., Conkle D., Seipp C. A., Levine A. S., Simon R. M. Treatment of osteogenic sarcoma. II. Aggressive resection of pulmonary metastases. Cancer Treat Rep. 1979 May;63(5):753–756. [PubMed] [Google Scholar]
- Stromeyer F. W., Ishak K. G., Gerber M. A., Mathew T. Ground-glass cells in hepatocellular carcinoma. Am J Clin Pathol. 1980 Sep;74(3):254–258. doi: 10.1093/ajcp/74.3.254. [DOI] [PubMed] [Google Scholar]
- Thomas P. Studies on the mechanisms of biliary excretion of circulating glycoproteins. The carcinoembryonic antigen. Biochem J. 1980 Dec 15;192(3):837–843. doi: 10.1042/bj1920837. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Thung S. N., Gerber M. A., Sarno E., Popper H. Distribution of five antigens in hepatocellular carcinoma. Lab Invest. 1979 Aug;41(2):101–105. [PubMed] [Google Scholar]
- Vogel C. L., Bayley A. C., Brooker R. J., Anthony P. P., Ziegler J. L. A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United States. Cancer. 1977 May;39(5):1923–1929. doi: 10.1002/1097-0142(197705)39:5<1923::aid-cncr2820390502>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
- Wong L. K., Link D. P., Frey C. F., Ruebner R. H., Tesluk H., Pimstone N. R. Fibrolamellar hepatocarcinoma: radiology, management, and pathology. AJR Am J Roentgenol. 1982 Jul;139(1):172–175. doi: 10.2214/ajr.139.1.172. [DOI] [PubMed] [Google Scholar]